Sanofi (SNY) Shares Sold by Harbour Capital Advisors LLC
Harbour Capital Advisors LLC lessened its position in shares of Sanofi (NYSE:SNY) by 92.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,600 shares of the company’s stock after selling 111,175 shares during the quarter. Harbour Capital Advisors LLC’s holdings in Sanofi were worth $428,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. Pacer Advisors Inc. grew its stake in Sanofi by 16.9% during the 3rd quarter. Pacer Advisors Inc. now owns 64,852 shares of the company’s stock valued at $3,229,000 after purchasing an additional 9,396 shares during the last quarter. Girard Partners LTD. acquired a new position in shares of Sanofi in the 3rd quarter valued at about $342,000. Edge Advisors LLC lifted its holdings in shares of Sanofi by 6.2% in the 3rd quarter. Edge Advisors LLC now owns 176,365 shares of the company’s stock valued at $8,780,000 after buying an additional 10,369 shares during the period. Regal Investment Advisors LLC acquired a new position in shares of Sanofi in the 3rd quarter valued at about $241,000. Finally, Macquarie Group Ltd. lifted its holdings in shares of Sanofi by 1.1% in the 3rd quarter. Macquarie Group Ltd. now owns 2,622,391 shares of the company’s stock valued at $130,569,000 after buying an additional 29,045 shares during the period. Institutional investors and hedge funds own 9.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Sanofi (SNY) Shares Sold by Harbour Capital Advisors LLC” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/21/sanofi-sny-shares-sold-by-harbour-capital-advisors-llc.html.
Several equities analysts have recently issued reports on SNY shares. BidaskClub cut Sanofi from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Cowen and Company reissued a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. raised Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Argus reissued a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a report on Friday, September 1st. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and a consensus target price of $53.50.
In other Sanofi news, major shareholder Sanofi purchased 105,820 shares of Sanofi stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average price of $482.04 per share, with a total value of $51,009,472.80. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.00% of the company’s stock.
Sanofi (NYSE SNY) traded down $0.22 during midday trading on Tuesday, reaching $44.32. The company had a trading volume of 613,700 shares, compared to its average volume of 1,516,191. The firm has a market cap of $112,190.00, a PE ratio of 14.05, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88. Sanofi has a 12 month low of $38.45 and a 12 month high of $50.65. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.